Roxbury Financial’s Pacira BioSciences PCRX Stock Holding History

Roxbury Financial’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,222	Closed	-$161K	–	404
2025 Q4	$161K	Buy	+6,222	New	+$148K	0.14%	104

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Roxbury Financial's PCRX Position: Q1 2026 in Review

Roxbury Financial sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 6,222 shares — an estimated $161K sold.

Roxbury Financial first reported a position in PCRX in Q4 2025 and held it in 1 quarter. The position peaked at $161K in Q4 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Roxbury Financial reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Roxbury Financial sold 6,222 Pacira BioSciences shares in Q1 2026, an estimated $161K.
Roxbury Financial first reported a position in Pacira BioSciences in Q4 2025 and held it in 1 quarter.
Roxbury Financial's Pacira BioSciences position peaked at $161K in Q4 2025.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Roxbury Financial's 13F filing for Q1 2026, filed 17 Apr 2026.